Pacific Edge (NZE:PEB, ASX:PEB) reported a 6.8% increase in tests processed at its laboratories in the fourth quarter of fiscal 2025 compared with the prior three-month period, according to a Friday filing with the Australian and New Zealand bourses.
Total laboratory throughput rose to 7,577 tests from 7,092 tests between the third and fourth fiscal quarters.
However, total volumes for the full fiscal year ended March declined nearly 12% to 28,894 tests from 32,633 in the prior fiscal year. The decline reflected lower sales force due to the uncertainty over Medicare coverage of Cxbladder, per the filing.
Pacific Edge's shares were up 3% in New Zealand and by 4% in Australia in recent Friday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。